Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era
Authors
Keywords
-
Journal
LEUKEMIA & LYMPHOMA
Volume 56, Issue 5, Pages 1213-1222
Publisher
Informa UK Limited
Online
2014-08-18
DOI
10.3109/10428194.2014.941836
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Recurrent targets of aberrant somatic hypermutation in lymphoma
- (2015) Alireza Hadj Khodabakhshi et al. Oncotarget
- Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors
- (2014) Jimin Woo et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma
- (2014) V. Fresquet et al. BLOOD
- Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment
- (2014) Xiaohui Zheng et al. Cancer Cell International
- Impact of tumor sequencing on the use of anticancer drugs
- (2014) François Thomas et al. CURRENT OPINION IN ONCOLOGY
- Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies
- (2014) E. Jabbour et al. HAEMATOLOGICA
- Consequences of the recurrentMYD88L265Psomatic mutation for B cell tolerance
- (2014) James Q. Wang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
- (2014) S. K. Knutson et al. MOLECULAR CANCER THERAPEUTICS
- Discovery and saturation analysis of cancer genes across 21 tumour types
- (2014) Michael S. Lawrence et al. NATURE
- Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma
- (2014) Jay Gunawardana et al. NATURE GENETICS
- Clinicopathologic Characterization of Diffuse-Large-B-Cell Lymphoma with an Associated Serum Monoclonal IgM Component
- (2014) M. Christina Cox et al. PLoS One
- High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells
- (2014) Lesley A. Mathews Griner et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma
- (2014) S M Ansell et al. Blood Cancer Journal
- Genome sequencing of lymphoid malignancies
- (2013) C. G. Mullighan BLOOD
- EZH2 mutations are frequent and represent an early event in follicular lymphoma
- (2013) C. Bodor et al. BLOOD
- Analysis of FOXO1 mutations in diffuse large B-cell lymphoma
- (2013) D. L. Trinh et al. BLOOD
- Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing
- (2013) R. D. Morin et al. BLOOD
- EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation
- (2013) Wendy Béguelin et al. CANCER CELL
- EZH2andCD79Bmutational status over time in B-cell non-Hodgkin lymphomas detected by high-throughput sequencing using minimal samples
- (2013) Mauro Ajaj Saieg et al. CANCER CYTOPATHOLOGY
- Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth
- (2013) Shivani Garapaty-Rao et al. CHEMISTRY & BIOLOGY
- Molecular Pathways: Targeting MALT1 Paracaspase Activity in Lymphoma
- (2013) L. Fontan et al. CLINICAL CANCER RESEARCH
- Targeting the Toll-like Receptor/Interleukin 1 Receptor Pathway in Human Diseases: Rational Design of MyD88 Inhibitors
- (2013) Maria Loiarro et al. Clinical Lymphoma Myeloma & Leukemia
- Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update
- (2013) Gubbi M Arunesh et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma
- (2013) Elodie Bohers et al. GENES CHROMOSOMES & CANCER
- MYD88 expression and L265P mutation in diffuse large B-cell lymphoma
- (2013) Jung-Woo Choi et al. HUMAN PATHOLOGY
- CD79B and MYD88 mutations in diffuse large B-cell lymphoma
- (2013) Yuil Kim et al. HUMAN PATHOLOGY
- Reprogramming cell death: BCL2 family inhibition in hematological malignancies
- (2013) Lydia Scarfò et al. IMMUNOLOGY LETTERS
- Mutational Analysis Identifies Residues Crucial for Homodimerization of Myeloid Differentiation Factor 88 (MyD88) and for Its Function in Immune Cells
- (2013) Maria Loiarro et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Nuclear Factor-κB Pathway–Activating Gene Aberrancies in Primary Cutaneous Large B-Cell Lymphoma, Leg Type
- (2013) Lianne Koens et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Comparison of Clinical Targeted Next-Generation Sequence Data from Formalin-Fixed and Fresh-Frozen Tissue Specimens
- (2013) David H. Spencer et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Targeted, High-Depth, Next-Generation Sequencing of Cancer Genes in Formalin-Fixed, Paraffin-Embedded and Fine-Needle Aspiration Tumor Specimens
- (2013) Andrew G. Hadd et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma
- (2013) W Kraan et al. LEUKEMIA
- Next-generation sequencing of cancer consensus genes in lymphoma
- (2013) Jennifer Hüllein et al. LEUKEMIA & LYMPHOMA
- Polycomb protein EZH2 expression in diffuse large B-cell lymphoma is associated with better prognosis in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone
- (2013) Hyun Jung Lee et al. LEUKEMIA & LYMPHOMA
- Targeted disruption of the EZH2–EED complex inhibits EZH2-dependent cancer
- (2013) Woojin Kim et al. Nature Chemical Biology
- Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma
- (2013) Jessica Okosun et al. NATURE GENETICS
- MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma
- (2013) Carol Y Ying et al. NATURE IMMUNOLOGY
- Diffuse large B-cell lymphoma—treatment approaches in the molecular era
- (2013) Mark Roschewski et al. Nature Reviews Clinical Oncology
- Emerging patterns of somatic mutations in cancer
- (2013) Ian R. Watson et al. NATURE REVIEWS GENETICS
- Genetic heterogeneity of diffuse large B-cell lymphoma
- (2013) Jenny Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- B-cell receptor signaling as a driver of lymphoma development and evolution
- (2013) Carsten U. Niemann et al. SEMINARS IN CANCER BIOLOGY
- High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites
- (2013) W Kraan et al. Blood Cancer Journal
- Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma
- (2013) T. Clozel et al. Cancer Discovery
- CONTRA: copy number analysis for targeted resequencing
- (2012) Jason Li et al. BIOINFORMATICS
- TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma
- (2012) D. W. Scott et al. BLOOD
- Epigenetic Therapy Leaps Ahead with Specific Targeting of EZH2
- (2012) Ari Melnick CANCER CELL
- Pharmacologic Inhibition of MALT1 Protease by Phenothiazines as a Therapeutic Approach for the Treatment of Aggressive ABC-DLBCL
- (2012) Daniel Nagel et al. CANCER CELL
- Inhibitors of B-Cell Receptor Signaling for Patients With B-Cell Malignancies
- (2012) Michael Y. Choi et al. CANCER JOURNAL
- Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System Lymphomas
- (2012) A. Gonzalez-Aguilar et al. CLINICAL CANCER RESEARCH
- The role of activation-induced cytidine deaminase in lymphomagenesis
- (2012) Xiwen Gu et al. CURRENT OPINION IN HEMATOLOGY
- A687V EZH2 is a gain-of-function mutation found in lymphoma patients
- (2012) Christina R. Majer et al. FEBS LETTERS
- Janus Reveals Another Face: The Biologic Rationale for Targeting Janus Kinase 2 in Lymphoma
- (2012) Ann Mullally et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
- (2012) Ranjana H. Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Human lymphoma mutations reveal CARD11 as the switch between self-antigen–induced B cell death or proliferation and autoantibody production
- (2012) Yogesh S. Jeelall et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The coding genome of splenic marginal zone lymphoma: activation ofNOTCH2and other pathways regulating marginal zone development
- (2012) Davide Rossi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Congenital B cell lymphocytosis explained by novel germlineCARD11mutations
- (2012) Andrew L. Snow et al. JOURNAL OF EXPERIMENTAL MEDICINE
- MYD88 Somatic Mutation Is a Genetic Feature of Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
- (2012) Anne Pham-Ledard et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas
- (2012) N Gachard et al. LEUKEMIA
- A Quantitative Signaling Screen Identifies CARD11 Mutations in the CARD and LATCH Domains That Induce Bcl10 Ubiquitination and Human Lymphoma Cell Survival
- (2012) W. Chan et al. MOLECULAR AND CELLULAR BIOLOGY
- EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
- (2012) Michael T. McCabe et al. NATURE
- MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia
- (2012) Steven P. Treon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)
- (2012) M. T. McCabe et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PIM1 gene cooperates with human BCL6 gene to promote the development of lymphomas
- (2012) B. W. Baron et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing
- (2012) J. G. Lohr et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The molecular pathogenesis of primary mediastinal large B-cell lymphoma
- (2011) C. Steidl et al. BLOOD
- Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma
- (2011) R. Kridel et al. BLOOD
- Targeted high throughput sequencing in clinical cancer Settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity
- (2011) Martin Kerick et al. BMC Medical Genomics
- Mutations of CD79A, CD79B and EZH2 genes in immunodeficiency-related non-Hodgkin lymphomas
- (2011) Daniela Capello et al. BRITISH JOURNAL OF HAEMATOLOGY
- Protein Kinase C Inhibitor Sotrastaurin Selectively Inhibits the Growth of CD79 Mutant Diffuse Large B-Cell Lymphomas
- (2011) T. L. Naylor et al. CANCER RESEARCH
- B cell antigen receptor-induced activation of an IRAK4-dependent signaling pathway revealed by a MALT1-IRAK4 double knockout mouse model
- (2011) Almut Dufner et al. Cell Communication and Signaling
- A20, ABIN-1/2, and CARD11 Mutations and Their Prognostic Value in Gastrointestinal Diffuse Large B-Cell Lymphoma
- (2011) Gehong Dong et al. CLINICAL CANCER RESEARCH
- The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age
- (2011) S. Mareschal et al. HAEMATOLOGICA
- BCL2 mutations in diffuse large B-cell lymphoma
- (2011) J M Schuetz et al. LEUKEMIA
- Inactivating mutations of acetyltransferase genes in B-cell lymphoma
- (2011) Laura Pasqualucci et al. NATURE
- Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
- (2011) Ryan D. Morin et al. NATURE
- MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
- (2011) Christian Steidl et al. NATURE
- Analysis of the coding genome of diffuse large B-cell lymphoma
- (2011) Laura Pasqualucci et al. NATURE GENETICS
- BRAFMutations in Hairy-Cell Leukemia
- (2011) Enrico Tiacci et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutations of CARD11 but not TNFAIP3 may activate the NF-κB pathway in primary CNS lymphoma
- (2010) Manuel Montesinos-Rongen et al. ACTA NEUROPATHOLOGICA
- Oncogenic CARD11 Mutations Induce Hyperactive Signaling by Disrupting Autoinhibition by the PKC-Responsive Inhibitory Domain
- (2010) Rebecca L. Lamason et al. BIOCHEMISTRY
- Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation
- (2010) D. B. Yap et al. BLOOD
- CAL-101, a p110 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
- (2010) B. J. Lannutti et al. BLOOD
- Oncogenically active MYD88 mutations in human lymphoma
- (2010) Vu N. Ngo et al. NATURE
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
- (2010) R. Eric Davis et al. NATURE
- Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
- (2010) Ryan D Morin et al. NATURE GENETICS
- Aggressive Lymphomas
- (2010) Georg Lenz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Critical role of PI3K signaling for NF- B-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells
- (2010) B. Kloo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Syk is a dual-specificity kinase that self-regulates the signal output from the B-cell antigen receptor
- (2010) B. Heizmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas
- (2010) C. J. Sneeringer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
- (2009) J. W. Friedberg et al. BLOOD
- Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
- (2009) Mara Compagno et al. NATURE
- Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma
- (2009) S. Hailfinger et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Balancing AID and DNA repair during somatic hypermutation
- (2009) Man Liu et al. TRENDS IN IMMUNOLOGY
- Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma
- (2008) G. Lenz et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search